YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth r…
Investing.com - U.S. stock index futures hovered around the flatline on Tuesday after soaring bond yields dented Wall Street in the prior session, as investors looked ahead to a fresh batch of economic data. Still guessing which names to b…
AbCellera Biologics ABCL has delivered a sharp rally over the past three months, with the stock soaring 121% compared with the industry's 6.6% growth. The move has been driven primarily by a combination of strong clinical progress for its…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial results from its drug candidate for hot flas…
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseas…
AbCellera Biologics (ABCL [https://seekingalpha.com/symbol/ABCL]) announced the pricing of its oversubscribed underwritten public offering [https://seekingalpha.com/pr/20617674-abcellera-announces-pricing-of-oversubscribed-200-million-publ…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Chief Legal and Compliance Officer - Tryn Stimart President and Chief Executive Officer - Carl L. Hansen Chief Financial Officer - Andrew Booth F…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest analyst update on AbCellera Biologics reflects a higher…
Intel Corporation (INTC) shares fell 4.1% after the company announced a $15 billion stock offering to support capital spending, working capital and future growth. MarineMax, Inc. (HZO) shares surged 46.1% after agreeing to be acquired by B…
(RTTNews) - The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials. Silence Therapeutics plc (SLN) Silence…
AbCellera Biologics Inc. (NASDAQ:ABCL) rallied for a third consecutive day on Monday to hit a new three-year high, after its drug candidate for hot flashes in menopausal women achieved strong clinical trial results, sparking long-term rosy…
Check out some of the companies making the biggest moves midday: MarineMax — The boat and yacht retailer soared 46% after agreeing to be sold to Blackstone Infrastructure's Safe Harbor Marinas for $53 a share in cash, or $1.5 billion. The…
(Bloomberg) -- Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial. Most Read from Bloomberg Chi…
New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading
(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor sympt…
(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), common…
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed en…
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring i…
Jazz Pharmaceuticals JAZZ reported second-quarter 2026 adjusted earnings per share (EPS) of $5.71, which missed the Zacks Consensus Estimate of $6.04. This shortfall primarily reflected $77 million in acquired in-process research and devel…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration…
VANCOUVER, British Columbia, July 29, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecifi…
Issued on behalf of MindWalk Holdings Corp. MindWalk Holdings Corp. (NASDAQ: HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AbCellera Biologics Inc. (ABCL) been one of those stocks this year? A quick glance at the company's year-to-date perfor…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny…
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor Sandor, M.D.C.M, to its Board of Director…
Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on MNKD. MannKind Corporation's share was trading at $3.8400 as of Jun…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
AbCellera Biologics Inc. (ABCL) shares rallied 7.1% in the last trading session to close at $6.03. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
Enanta Pharmaceuticals (ENTA) shares rallied 5.2% in the last trading session to close at $14.06. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the s…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Jazz Pharmaceuticals (NasdaqGS:JAZZ) expanded its collaboration with AbCellera Biologics to devel…
AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks.On June 17, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. T…
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas includ…
Jazz Pharmaceuticals JAZZ announced a preclinical research collaboration deal with AbCellera Biologics ABCL to discover and develop next-generation T-cell-engaging (TCE) multispecific antibodies for gastrointestinal (GI) cancers and other…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is AbCellera Biologics Inc. (ABCL) one of those stocks right now? Let's take a closer look at the stock's year-to-date perf…
medical research red syringe NEW SIZE ©rawpixel Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbCellera (NASDAQ:ABCL) have signed a preclinical collaboration, option and licensing agreement focused on the discovery and development of T-cell engag…